---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-22-000049"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:01:10.560253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prothena earns $40M milestone from Novo Nordisk for ATTR cardiomyopathy drug advance

## Summary
- $40 million milestone payment from Novo Nordisk triggered by continued Phase 2 study of NNC6019 for ATTR cardiomyopathy.
- Total potential milestone payments up to $1.2 billion; $100 million earned to date including this payment.
- Novo Nordisk acquired full worldwide rights to ATTR amyloidosis pipeline from Prothena in July 2021.
- Phase 2 study addresses high unmet need in moderate to advanced ATTR amyloidosis with risk of early mortality.

## SEC filing metadata
- accession: 0001559053-22-000049
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000049/0001559053-22-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905322000049/prta-20221121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-22-000049
- JSON: https://secwatch.observer/filing/0001559053-22-000049.json
- Plain text: https://secwatch.observer/filing/0001559053-22-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.